Efficacy and safety of a once-daily fixed-dose combination of abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL3001 study)

Article Abstract:

A study to compare the efficacy and safety of the fixed-dose combination group to the separate entities group, in combination with tenofovir and a new protease inhibitor or nonnucleoside reverse transcription inhibitor in antiretroviral-experienced adults experiencing virologic failure is illustrated. Combination antiretroviral therapy has dramatically reduced the morbidity and mortality associated with HIV infection and a one-tablet, once-daily abacavir/lamivudine (FDC) has been recently approved to treat HIV-1 infection.

United States, Comparative analysis, Lamivudine, Abacavir, Tenofovir

---

Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration

Article Abstract:

The effect of rifampicin on steady-state pharmacokinetics of nevirapine and the impact of increasing the dose of nevirapine on its peak [C.sub.max] and through [C.sub.min] levels in 13 HIV infected patients is studied on regular antiretroviral treatment with nevirapine containing regimens (200mg). Findings suggest that decreased bioavailability of nevirapine because of rifampicin coadministration could be overcome by increasing the dose of nevirapine from 200 to 300 mg twice daily without short-term adverse events.

Rifampin, Disease/Disorder overview

---

Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: A preliminary report on the Nigerian antiretroviral program

Article Abstract:

A study was conducted to evaluate treatment outcome in the first 12 months among HIV-positive patients managed with a combination of nevirapine, stavudine, and lamivudine under the national antiretroviral (ARV) program in Nigeria. The overall results within the 12-month treatment period indicated an effective suppression of viral replication, the reconstitution of the immune system, and improvement of the physical well being of the population.

Nigeria, Care and treatment, Diagnosis, HIV patients

Similar abstracts:

• Abstracts: Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL)
• Abstracts: Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: A pilot study
• Abstracts: Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients
• Abstracts: Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: The Swiss HIV cohort study
• Abstracts: Moving from theory to research practice: Implementing an effective dyadic intervention to improve antiretroviral adherence for clinic patients

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.